The Roles of Prostanoids in Patients With Sleep Apnea Syndrome
Keywords
Abstract
Description
SAS is characterized by abnormality during sleep and hypoxemia from apnea and hypopnea, followed by systemic inflammation and organ dysfunction like cardiovascular diseases. Systemic inflammation causes the activation of arachidonic acid metabolism, producing prostaglandins (PGs) and leukotrienes (LTs). In addition, significant relationships between PGD2 and PGE2 and sleep, PGF2α and hypertension, PGI2 and thromboxane and platelet aggregation and so on are reported. Therefore, it is hypothesized that many prostanoids affect the pathophysiology of SAS. However, the relationships between prostanoids and clinical outcomes in patients with SAS are unknown. Although CPAP is the major treatment of SAS, the effects of CPAP on prostanoids are not known, either. Thus, the purpose of this study is to evaluate those relationships.
Dates
| Last Verified: | 02/28/2013 |
| First Submitted: | 11/16/2009 |
| Estimated Enrollment Submitted: | 11/16/2009 |
| First Posted: | 11/17/2009 |
| Last Update Submitted: | 03/24/2013 |
| Last Update Posted: | 03/26/2013 |
| Actual Study Start Date: | 11/30/2009 |
| Estimated Primary Completion Date: | 02/28/2013 |
| Estimated Study Completion Date: | 02/28/2013 |
Condition or disease
Intervention/treatment
Device: CPAP
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: CPAP the subjects introduced with CPAP treatment | Device: CPAP CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects. |
Eligibility Criteria
| Ages Eligible for Study | 20 Years To 20 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Subjects hospitalized in Kyoto University Hospital for careful examination of SAS Exclusion Criteria: - Subjects with severe respiratory diseases, severe heart diseases, severe vascular diseases, or severe diabetes mellitus. - Subjects taking nonsteroidal anti-inflammatory drugs, steroids or immunosuppressants. |
Outcome
Primary Outcome Measures
1. metabolites of arachidonic acid in the urine and blood [3 months]
Secondary Outcome Measures
1. Polysomnography measurements [3 months]
2. Sleepiness and health-related quality of life [3 months]
3. Blood pressure and pulse rate [3 months]
4. Endothelial dysfunction [3 months]
5. Platelet aggregation [3 months]
6. Cardiac and neck echo cardiography [3 months]
